Monoamine-depleting agent: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
''' | {{Short description|A class of drugs that deplete monoamines in the brain}} | ||
== Overview == | |||
A '''monoamine-depleting agent''' is a type of [[pharmacological agent]] that reduces the levels of [[monoamines]] in the [[central nervous system]]. Monoamines are a group of neurotransmitters that include [[serotonin]], [[dopamine]], and [[norepinephrine]]. These neurotransmitters play a crucial role in regulating mood, arousal, and cognition. | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Monoamine-depleting agents work by interfering with the storage and release of monoamines in the [[synaptic vesicles]] of [[neurons]]. One of the primary mechanisms is the inhibition of the [[vesicular monoamine transporter]] (VMAT), which is responsible for transporting monoamines into synaptic vesicles. By inhibiting VMAT, these agents prevent the accumulation of monoamines in the vesicles, leading to their depletion in the synaptic cleft. | |||
Monoamine-depleting agents | == Clinical Uses == | ||
Monoamine-depleting agents are used in the treatment of various [[psychiatric]] and [[neurological disorders]]. They are particularly effective in managing conditions such as [[hypertension]], [[schizophrenia]], and [[Huntington's disease]]. | |||
== | === Hypertension === | ||
In the treatment of [[hypertension]], monoamine-depleting agents help lower blood pressure by reducing the levels of norepinephrine, which decreases [[sympathetic nervous system]] activity. | |||
=== Schizophrenia === | |||
For patients with [[schizophrenia]], these agents can help alleviate symptoms by reducing dopamine levels, which are often elevated in this condition. | |||
=== Huntington's Disease === | |||
In [[Huntington's disease]], monoamine-depleting agents can help manage chorea, a movement disorder associated with the disease, by depleting dopamine. | |||
== Side Effects == | == Side Effects == | ||
The use of monoamine-depleting agents can lead to several side effects due to the reduction of monoamines. Common side effects include [[depression]], [[sedation]], and [[gastrointestinal disturbances]]. | |||
The | |||
== Examples == | == Examples == | ||
One of the most well-known monoamine-depleting agents is [[reserpine]]. Reserpine is derived from the [[Rauwolfia serpentina]] plant and has been used historically in the treatment of hypertension and psychotic disorders. | |||
[[File:Reserpine.svg|thumb|right|Chemical structure of Reserpine]] | |||
== Related Pages == | |||
* [[Monoamine neurotransmitter]] | * [[Monoamine neurotransmitter]] | ||
* [[Vesicular monoamine transporter]] | |||
* [[Reserpine]] | |||
* [[Neurotransmitter]] | * [[Neurotransmitter]] | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Neurotransmitters]] | [[Category:Neurotransmitters]] | ||
[[Category: | [[Category:Psychiatric drugs]] | ||
Latest revision as of 11:10, 15 February 2025
A class of drugs that deplete monoamines in the brain
Overview[edit]
A monoamine-depleting agent is a type of pharmacological agent that reduces the levels of monoamines in the central nervous system. Monoamines are a group of neurotransmitters that include serotonin, dopamine, and norepinephrine. These neurotransmitters play a crucial role in regulating mood, arousal, and cognition.
Mechanism of Action[edit]
Monoamine-depleting agents work by interfering with the storage and release of monoamines in the synaptic vesicles of neurons. One of the primary mechanisms is the inhibition of the vesicular monoamine transporter (VMAT), which is responsible for transporting monoamines into synaptic vesicles. By inhibiting VMAT, these agents prevent the accumulation of monoamines in the vesicles, leading to their depletion in the synaptic cleft.
Clinical Uses[edit]
Monoamine-depleting agents are used in the treatment of various psychiatric and neurological disorders. They are particularly effective in managing conditions such as hypertension, schizophrenia, and Huntington's disease.
Hypertension[edit]
In the treatment of hypertension, monoamine-depleting agents help lower blood pressure by reducing the levels of norepinephrine, which decreases sympathetic nervous system activity.
Schizophrenia[edit]
For patients with schizophrenia, these agents can help alleviate symptoms by reducing dopamine levels, which are often elevated in this condition.
Huntington's Disease[edit]
In Huntington's disease, monoamine-depleting agents can help manage chorea, a movement disorder associated with the disease, by depleting dopamine.
Side Effects[edit]
The use of monoamine-depleting agents can lead to several side effects due to the reduction of monoamines. Common side effects include depression, sedation, and gastrointestinal disturbances.
Examples[edit]
One of the most well-known monoamine-depleting agents is reserpine. Reserpine is derived from the Rauwolfia serpentina plant and has been used historically in the treatment of hypertension and psychotic disorders.
